/Investor DB

MB Venture Partners — Full Portfolio

5 tracked investments · listed companies and verified rows first

Hapten Scienceshaptensciences.comMay 2013SEC filingmedium confidence

Hapten Sciences develops early-stage pharmaceutical products focused on dermatological health, with its lead candidate PDC-APB in clinical development as a preventive immunotherapy for contact dermatitis caused by exposure to poisonous plants.

BiotechHealthtechMedical DevicesMemphis, US

Raymond J Hage(Executive Officer, Director, Promoter)

BoardGary Prosterman(Executive Officer, Director, Promoter)Stephen I. Bandak(Director)

Board seatGary Stevenson· per SEC Form D · $1.2M raise · filed Feb 2017

Ortho Kinematicsorthokinematics.comApr 2015 · $9.6M

HealthtechAustin, US

Paul Gunnoe(Executive Officer, Director)Adam Deitz(Executive Officer, Director)

BoardJohn Rodakis(Director)Gerald L. DeVries, Jr.(Director)Gary Stevenson(Director)Nelson Jaeggli(Director)

Co-investorsTEXO Ventures

Somavacsomavac.comin𝕏Oct 2017

SOMAVAC makes a smart surgical drain pump that delivers continuous sensor-controlled negative pressure therapy to the deep wound space, replacing traditional JP bulb drains and enabling earlier drain removal after surgery.

HardwareHealthtechMedical DevicesMemphis, US

Elizabeth Hoff(CEO)in

Co-investorsInnova Memphis, Inc.Launch Tennessee

SweetBiosweetbio.comin𝕏Aug 2018

SweetBio develops wound care dressings that combine collagen and Mānuka honey to help close chronic and acute non-healing wounds.

BiotechHealthtechMedical DevicesMemphis, US

Isaac Rodriguez(Executive Officer, Director)inKayla Rodriguez(Executive Officer, Director)inMarsalas Whitaker(Executive Officer, Director)inKevin Graff(Executive Officer)

Co-investorsInnova Memphis, Inc.Launch TennesseeVamosVenturesInnova

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Hubble Telemedical

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.